While there is an ongoing phase I clinical trial for prexasertib in pediatric patients (NCT02808650; Supplementary Table 3), including those with NB, a clear biomarker for CHK1 inhibition has yet to be identified. Here, CHEK1 is linked to neuroblastoma.